Cargando…

Multi-Agent Chemotherapy Overcomes Glucocorticoid Resistance Conferred by a BIM Deletion Polymorphism in Pediatric Acute Lymphoblastic Leukemia

A broad range of anti-cancer agents, including glucocorticoids (GCs) and tyrosine kinase inhibitors (TKIs), kill cells by upregulating the pro-apoptotic BCL2 family member, BIM. A common germline deletion in the BIM gene was recently shown to favor the production of non-apoptotic BIM isoforms, and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soh, Sheila Xinxuan, Lim, Joshua Yew Suang, Huang, John W. J., Jiang, Nan, Yeoh, Allen Eng Juh, Ong, S. Tiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121131/ https://www.ncbi.nlm.nih.gov/pubmed/25090024 http://dx.doi.org/10.1371/journal.pone.0103435

Ejemplares similares

Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides
por: Liu, Jun, et al.
Publicado: (2017)

The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia
por: Rauzan, Muhammad, et al.
Publicado: (2017)

Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia
por: Sarno, Jolanda, et al.
Publicado: (2023)

Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM
por: Matheson, Elizabeth C., et al.
Publicado: (2019)

Genetic predisposition to B-cell acute lymphoblastic leukemia at 14q11.2 is mediated by a CEBPE promoter polymorphism
por: Studd, James B., et al.
Publicado: (2018)

Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression
por: Toscan, Cara E., et al.
Publicado: (2020)

Overcoming Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: Repurposed Drugs Can Improve the Protocol
por: Olivas-Aguirre, Miguel, et al.
Publicado: (2021)

Oncorequisite role of an aldehyde dehydrogenase in the pathogenesis of T-cell acute lymphoblastic leukemia
por: Zhang, Chujing, et al.
Publicado: (2020)

Mutational profiling of acute lymphoblastic leukemia with testicular relapse
por: Ding, Ling-Wen, et al.
Publicado: (2017)

The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia
por: Ko, Tun Kiat, et al.
Publicado: (2015)

Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia
por: Lim, Fang Qi, et al.
Publicado: (2022)

Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia
por: Zhao, Xujie, et al.
Publicado: (2022)

GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy
por: Heidari, N, et al.
Publicado: (2010)

RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia
por: Koschut, David, et al.
Publicado: (2020)

Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells
por: Heidari, N, et al.
Publicado: (2012)

CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition
por: Meyer, Lauren K., et al.
Publicado: (2019)

Overcoming Steroid Resistance in T Cell Acute Lymphoblastic Leukemia
por: Goossens, Steven, et al.
Publicado: (2016)

Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia
por: Reynolds, Christine, et al.
Publicado: (2014)

BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia
por: Li, Yulin, et al.
Publicado: (2016)

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
por: Soh, Sheila X., et al.
Publicado: (2017)

JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias
por: Delgado-Martin, C, et al.
Publicado: (2017)

Identification of cis-Acting Elements and Splicing Factors Involved in the Regulation of BIM Pre-mRNA Splicing
por: Juan, Wen Chun, et al.
Publicado: (2014)

The prognostic value of glucocorticoid receptors for adult acute lymphoblastic leukemia
por: Bedewy, Ahmed M. L., et al.
Publicado: (2015)

MEK Inhibitors Potentiate Dexamethasone Lethality in Acute Lymphoblastic Leukemia Cells through the Pro-apoptotic Molecule BIM
por: Rambal, Anila A., et al.
Publicado: (2009)

BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors
por: Korfi, K, et al.
Publicado: (2016)

Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia
por: Follini, Elena, et al.
Publicado: (2019)

Salidroside overcomes dexamethasone resistance in T-acute lymphoblastic leukemia cells
por: Niu, Ya-Na, et al.
Publicado: (2021)

Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia
por: Li, Zhenhua, et al.
Publicado: (2021)

Metabolic reprogramming of acute lymphoblastic leukemia cells in response to glucocorticoid treatment
por: Dyczynski, Matheus, et al.
Publicado: (2018)

Gene Mutations Related to Glucocorticoid Resistance in Pediatric Acute Lymphoblastic Leukemia
por: Zhang, JinFang, et al.
Publicado: (2022)

Inhibition of the Sec61 translocon overcomes cytokine‐induced glucocorticoid resistance in T‐cell acute lymphoblastic leukaemia
por: Meyer, Lauren K., et al.
Publicado: (2022)

Glucocorticoids can induce BIM to trigger apoptosis in the absence of BAX and BAK1
por: Dong, Li, et al.
Publicado: (2020)

PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia, interferes with glucocorticoid-induced apoptosis
por: Wasim, Muhammad, et al.
Publicado: (2010)

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer
por: Takeuchi, Shinji, et al.
Publicado: (2020)

Reversal of glucocorticoid resistance in Acute Lymphoblastic Leukemia cells by miR-145
por: Long, Sili, et al.
Publicado: (2020)

Emerging Epigenetic and Posttranslational Mechanisms Controlling Resistance to Glucocorticoids in Acute Lymphoblastic Leukemia
por: Borin, Cristina, et al.
Publicado: (2023)

Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC
por: Incharoen, Pimpin, et al.
Publicado: (2019)

Curing the Curable: Managing Low-Risk Acute Lymphoblastic Leukemia in Resource Limited Countries
por: Oh, Bernice L. Z., et al.
Publicado: (2021)

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma
por: Tu, Yong-sheng, et al.
Publicado: (2017)

Gene Deletions and Prognostic Values in B-Linage Acute Lymphoblastic Leukemia
por: Fang, Qiuyun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bqh77lbmq4pc78m5hqdogoagdn